Review
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2012; 18(6): 498-506
Published online Feb 14, 2012. doi: 10.3748/wjg.v18.i6.498
Table 1 Response assessment by modified World Health Organization criteria and modified Response Evaluation Criteria in Solid Tumors
ParameterModified WHOModified RECIST
Type of assessmentSpiral CTSpiral CT or dynamic MRI
Frequency of assessment≥ 4 wk6-8 wk
Measurement of tumor volumeBidimensional measurementUnidimensional measurement
Tumor necrosis measurementReduction in viable tumor area using contrast-enhanced radiological imagingReduction in viable tumor area using contrast-enhanced radiological imaging
Viable tumor definitionEnhanced areas inside treatment lesionsUptake of contrast agent in the arterial phase
Complete responseComplete disappearance of tumor enhancement determined by 2 observations ≥ 4 wk apartDisappearance of any intratumoral arterial enhancement in all target lesions
Partial response> 50% reduction in total area of tumor enhancement determined by 2 observations ≥ 4 wk apart≥ 30% decrease in the sum of diameters of viable target lesions, taking as reference the baseline sum of the diameters of target lesions
Stable diseaseInsufficient shrinkage to qualify for partial response and insufficient increase to qualify for progressive diseaseAny cases that do not qualify for either partial response or progressive disease
Progressive disease> 25% increase in total area of tumor enhancement or the appearance of new lesions≥ 20% increase in the sum of the diameters of viable target lesions, taking as reference the smallest sum of the diameters of viable target lesions recorded since the treatment started or the appearance of 1 or more new lesions